Logo image of CRDF

CARDIFF ONCOLOGY INC (CRDF) Stock Fundamental Analysis

NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock

3.5  -0.02 (-0.57%)

Fundamental Rating

2

CRDF gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. CRDF has a great financial health rating, but its profitability evaluates not so good. CRDF does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRDF had negative earnings in the past year.
CRDF had a negative operating cash flow in the past year.
CRDF had negative earnings in each of the past 5 years.
In the past 5 years CRDF always reported negative operating cash flow.
CRDF Yearly Net Income VS EBIT VS OCF VS FCFCRDF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -68.37%, CRDF is doing worse than 65.31% of the companies in the same industry.
CRDF has a Return On Equity (-87.07%) which is in line with its industry peers.
Industry RankSector Rank
ROA -68.37%
ROE -87.07%
ROIC N/A
ROA(3y)-34.36%
ROA(5y)-49.48%
ROE(3y)-38.69%
ROE(5y)-72.52%
ROIC(3y)N/A
ROIC(5y)N/A
CRDF Yearly ROA, ROE, ROICCRDF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

CRDF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDF Yearly Profit, Operating, Gross MarginsCRDF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

CRDF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRDF has about the same amount of shares outstanding.
CRDF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRDF Yearly Shares OutstandingCRDF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CRDF Yearly Total Debt VS Total AssetsCRDF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

Based on the Altman-Z score of 0.58, we must say that CRDF is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.58, CRDF is in the better half of the industry, outperforming 65.66% of the companies in the same industry.
There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.58
ROIC/WACCN/A
WACC11.11%
CRDF Yearly LT Debt VS Equity VS FCFCRDF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

CRDF has a Current Ratio of 4.74. This indicates that CRDF is financially healthy and has no problem in meeting its short term obligations.
CRDF's Current ratio of 4.74 is in line compared to the rest of the industry. CRDF outperforms 51.68% of its industry peers.
CRDF has a Quick Ratio of 4.74. This indicates that CRDF is financially healthy and has no problem in meeting its short term obligations.
CRDF has a Quick ratio of 4.74. This is comparable to the rest of the industry: CRDF outperforms 53.27% of its industry peers.
Industry RankSector Rank
Current Ratio 4.74
Quick Ratio 4.74
CRDF Yearly Current Assets VS Current LiabilitesCRDF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for CRDF have decreased by -2.17% in the last year.
Looking at the last year, CRDF shows a very strong growth in Revenue. The Revenue has grown by 49.78%.
The Revenue has been growing slightly by 5.13% on average over the past years.
EPS 1Y (TTM)-2.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
Revenue 1Y (TTM)49.78%
Revenue growth 3Y9.67%
Revenue growth 5Y5.13%
Sales Q2Q%17.02%

3.2 Future

Based on estimates for the next years, CRDF will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.62% on average per year.
Based on estimates for the next years, CRDF will show a very negative growth in Revenue. The Revenue will decrease by -11.38% on average per year.
EPS Next Y-7.48%
EPS Next 2Y-0.69%
EPS Next 3Y-7.75%
EPS Next 5Y-11.62%
Revenue Next Year63.44%
Revenue Next 2Y-6.2%
Revenue Next 3Y-28.58%
Revenue Next 5Y-11.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRDF Yearly Revenue VS EstimatesCRDF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
CRDF Yearly EPS VS EstimatesCRDF Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRDF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDF Price Earnings VS Forward Price EarningsCRDF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDF Per share dataCRDF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as CRDF's earnings are expected to decrease with -7.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.69%
EPS Next 3Y-7.75%

More info and screens

0

5. Dividend

5.1 Amount

CRDF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIFF ONCOLOGY INC

NASDAQ:CRDF (1/22/2025, 1:04:05 PM)

3.5

-0.02 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners28.71%
Inst Owner Change-1.56%
Ins Owners2.07%
Ins Owner Change29.2%
Market Cap232.82M
Analysts83.64
Price Target11.22 (220.57%)
Short Float %15.14%
Short Ratio3.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.12%
Min EPS beat(2)-2.99%
Max EPS beat(2)9.22%
EPS beat(4)3
Avg EPS beat(4)11.22%
Min EPS beat(4)-2.99%
Max EPS beat(4)25.81%
EPS beat(8)6
Avg EPS beat(8)10.35%
EPS beat(12)8
Avg EPS beat(12)6.48%
EPS beat(16)10
Avg EPS beat(16)2.64%
Revenue beat(2)2
Avg Revenue beat(2)137.11%
Min Revenue beat(2)102.21%
Max Revenue beat(2)172.01%
Revenue beat(4)4
Avg Revenue beat(4)211.87%
Min Revenue beat(4)102.21%
Max Revenue beat(4)307.84%
Revenue beat(8)8
Avg Revenue beat(8)157.01%
Revenue beat(12)12
Avg Revenue beat(12)130.58%
Revenue beat(16)14
Avg Revenue beat(16)119.57%
PT rev (1m)17.86%
PT rev (3m)13.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.86%
EPS NY rev (1m)0%
EPS NY rev (3m)2.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.19%
Revenue NY rev (1m)1.01%
Revenue NY rev (3m)12.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 337.91
P/FCF N/A
P/OCF N/A
P/B 4.71
P/tB 4.71
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.01
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.37%
ROE -87.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.36%
ROA(5y)-49.48%
ROE(3y)-38.69%
ROE(5y)-72.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.66%
Cap/Sales 13.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.74
Quick Ratio 4.74
Altman-Z 0.58
F-Score4
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)204.58%
Cap/Depr(5y)134.54%
Cap/Sales(3y)145.52%
Cap/Sales(5y)104.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
EPS Next Y-7.48%
EPS Next 2Y-0.69%
EPS Next 3Y-7.75%
EPS Next 5Y-11.62%
Revenue 1Y (TTM)49.78%
Revenue growth 3Y9.67%
Revenue growth 5Y5.13%
Sales Q2Q%17.02%
Revenue Next Year63.44%
Revenue Next 2Y-6.2%
Revenue Next 3Y-28.58%
Revenue Next 5Y-11.38%
EBIT growth 1Y-4.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.62%
OCF growth 3YN/A
OCF growth 5YN/A